The Use of Home-monitoring and mHealth Systems to Predict Asthma Control and the Occurrence of Asthma Exacerbations

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-04-30

Study Completion Date

2018-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators will collect a range of physiological, behavioural and environmental data using current mHealth and home-monitoring systems, environmental databases and patient characteristics, to determine to what extent asthma control and the occurrence of asthma exacerbations can be predicted.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of the Impact of Exposure to Outdoor and Indoor Pollutants in Patients With Asthma

NCT05525169

Asthma

UNKNOWN

Evaluating Asthma Exacerbation-induced Changes in Lung Function With a Home-based Spirometer

NCT03705325

Asthma Asthma Attack Asthma, Allergic

COMPLETED NA

Bronchial Asthma & Its Exacerbation

NCT06331897

Bronchial Asthma

NOT_YET_RECRUITING

Asthma Breath Biomarker Assessment

NCT03084016

Asthma Acute

COMPLETED

Non-contact Proactive Remote Monitoring of COPD Exacerbations

NCT05598983

COPD Exacerbation

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This observational study occurs alongside participants' normal asthma care. Participants will be asked to attend their normal GP and hospital appointments, and to continue to take their medication as determined by their usual healthcare team.

In addition to their normal care, participants will attend an induction visit and complete a 12-month home-monitoring period with 2 phases:

* Phase 1: one-month period of daily monitoring of asthma
* Phase 2: eleven-month period of weekly monitoring of asthma. Patients will be invited for a further 2-week period of daily monitoring between 2-9 months of Phase 2. The purpose of the second phase of daily monitoring is to assess the influence of seasonality (different seasons) on the patient's asthma.

0 xxxx 1 ------ 2 ------ 3 ------ 4 yy-- 5 ------ 6------ 7 ------ 8 ------ 9 ------ 10 ------ 11 ----- 12

Figure 1. Schematic of study design. 0 1 2.., months; xxxx, first series of 4 weeks daily monitoring; ------ 11 months weekly monitoring; yy--, example of second series of 2 weeks daily monitoring during month 5 (the timing of this 2 weekly phase will be randomised over month 2-9).

A variety of measurements will be made at an induction visit and over the 12-month home-monitoring period, as detailed below:

Induction visit

Demographics - Age (yr), gender, nationality, ethnicity, body mass (kg), height (cm), body mass index (BMI), comorbidities, medication, previous moderate and severe asthma exacerbations in preceding 12 months, previous severe asthma exacerbations requiring hospital attendance / admission (No in preceding 12 months), number of intensive care admission for asthma (ever), smoking history and social economic status.

Questionnaires

* Asthma control will be assessed by the Asthma Control Questionnaire (ACQ). \[A patient's asthma control status will be classified as Controlled (ACQ≤0.75), Partly Controlled (0.75\<ACQ≤1.5) or Uncontrolled (ACQ\>1.5)\].
* The typical diet of participants will be assessed via the Global Allergy and Asthma European Network (GA2LEN) food frequency questionnaire.
* Sinusitis/rhinoconjunctivitis will be determined via the Sino-Nasal Outcome Test 22 (SNOT 22)
* Anxiety and depression will be determined via the hospital anxiety and depression score (HADS)
* Characteristics such as health directed behaviours and self-monitoring will be determined using the Health education impact Questionnaire (HeiQ)
* Mini-Asthma Quality of Life Questionnaire (mini-AQLQ)

Clinical tests

\- Atopic status will be determined via previous skin-prick test or blood test results.

(If a patient's atopic status is unknown, a standard skin-prick test or blood test will be conducted).

* The diagnosis of asthma will be verified via a previous test result, using one of the following; a bronchodilator reversibility test, one-week peak flow monitoring or a bronchial challenge test. (If a patient's asthma diagnosis has not been verified from one of the tests listed above, they may be performed at screening visits)
* Lung function (spirometry) will be conducted according to ERS guidelines
* Airways inflammation will be determined by the level of Fractional exhaled Nitric Oxide (FeNO) according to established guidelines
* Exhaled Breath Temperature, as measured by the X-halo device

Phase 1 (first 4-week daily monitoring)

The measurements in Phase 1 will be collected during the first 4 weeks of monitoring, and will be self-administered by the participant. Measurements will occur continuously, daily, weekly or less frequent, as specified below:

Questionnaires

* Daily, Asthma Control Diary (ACD)
* Daily, online medication diary
* Weekly, assessment of the occurrence of exacerbation, determined by a custom questionnaire.
* Monthly, mini Asthma Quality of Life Questionnaire (mini-AQLQ)
* Sinusitis will be determine via the SNOT 22 at the end of the first 4-week daily monitoring
* Technology acceptance via ASQ at the end of the first 4-week daily monitoring 25

Physiological monitoring

* Continuous data collection, via wearable sensors
* Pulse, exercise level via Fitbit HR wristband
* Medication usage and adherence via Smartinhaler device in a subset of 60 participants
* Measurement of breath rate via Spire device
* Daily, twice daily home spirometry (FEV1) via Piko-1 device
* Daily, twice-daily Fractional exhaled Nitric Oxide (FeNO) via NIOX-VERO device in a subset of 60 participants
* Daily, twice-daily Exhaled Breath Temperature (EBT) via X-halo device, in a subset of 60 participants

Environmental

* Retrospective collection of environmental conditions for patients home and work address, including:
* Ozone (O3)
* air pollution (PM10, PM2.5)
* ambient temperature
* Nitrous oxide (NO2)
* Sulphur dioxide (SO2)
* Weather conditions
* Mean temperature
* Humidity
* Pollen counts

Phase 2 (month 2-12) The measurements in Phase 2 will occur continuously, weekly or less frequent, as specified below. The weekly measurements will occur on a fixed day of the week, determined by participants for convenience, and all the measurements will be self-administered by the participant.

Questionnaires

* Weekly online Asthma Control Questionnaire
* Weekly assessment of the occurrence of exacerbation, determined by a custom questionnaire.
* Weekly, medication diary (custom made questionnaire)
* Monthly mini Asthma Quality of Life Questionnaire (mini AQLQ)
* Monthly, Sinus symptoms will be determine via the SNOT 22 questionnaire
* Technology acceptance via ASQ at 6 and 12 months
* Global Allergy and Asthma European Network (GA2LEN) food frequency questionnaire will be completed at the end of the study.

Physiological monitoring

* Continuous data collection, via wearable sensors
* Pulse, exercise level via Fitbit HR wristband
* Medication usage and adherence via Smartinhaler device in a subset of 60 participants
* Measurement of breath rate via Spire device
* Weekly, home spirometry (FEV1) via Piko-1
* Weekly, Fractional exhaled Nitric Oxide (FeNO) by NIOX-VERO in a subset of 60 participants
* Weekly, Exhaled Breath Temperature (EBT) by X-halo, in a subset of 60 participants

Environmental

\- Retrospective collection of environmental conditions for patients home and work address, as detailed above.

A second series daily monitoring (as described in phase 1) will be performed over a two week period, randomised between 2 to 9 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Doctors-diagnosis of asthma with confirmation of asthma from one or more of the following tests in medical notes:

i) Reversibility of 12% and 200ml in a spirometry following administration of a bronchodilator medication ii) Peak flow monitoring for one week iii) Positive bronchial challenge
2. BTS asthma treatment step 2-4, for a minimum of 6 months in the previous year
3. A course of oral prednisone for a minimum of three days, or an emergency department visit/hospitalisation for asthma, in the previous twelve months. Or currently experiencing uncontrolled asthma (based on the result of the Asthma Control Questionnaire)

Exclusion Criteria

1. Comorbidities that cause overlapping symptoms such as breathlessness, wheeze, cough or other interfering chronic condition (for example other symptomatic chronic respiratory disease, cardiac failure etc.).
2. Unable to understand English or Dutch, as appropriate

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No